Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cloudbreak PharmaHKSE:02592 +0.83%11 EV-to-FCF is -1.15 as of Aug. 10, 2026. GuruFocus rates HKSE:02592 with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 334 Biotechnology companies, Cloudbreak Pharma ranks worse than 299400.9% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cloudbreak Pharma's Enterprise Value is HK$625.53 Mil.
Cloudbreak Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-543.91 Mil. Therefore, Cloudbreak Pharma's EV-to-FCF for today is -1.15.
The historical rank and industry rank for Cloudbreak Pharma's EV-to-FCF or its related term are showing as below:
HKSE:02592'
s EV-to-FCF Range Over the Past 10 Years
Min: -32.21 Med: -9.84 Max: -1.12
Current: -1.15
During the past 4 years, the highest EV-to-FCF of Cloudbreak Pharma was -1.12. The lowest was -32.21. And the median was -9.84.
HKSE:02592's EV-to-FCF is ranked worse than 100% of 334
companies
in the Biotechnology industry
Industry Median: 17.55
vs HKSE:02592: -1.15
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cloudbreak Pharma's PE Ratio (TTM) for today is calculated as:
Cloudbreak Pharma's share price for today is HK$1.22.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cloudbreak Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-0.982.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cloudbreak Pharma EV-to-FCF Related Terms
Cloudbreak Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cloudbreak Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02592 vs VRTX, REGN, RVMD: EV-to-FCF Comparison
For the Biotechnology subindustry, Cloudbreak Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cloudbreak Pharma EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cloudbreak Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cloudbreak Pharma's EV-to-FCF falls into.
Cloudbreak Pharma's current Enterprise Value is HK$625.53 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cloudbreak Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$-543.91 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cloudbreak Pharma (HKSE:02592) has a EV-to-FCF of -1.15 as of Aug. 10, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cloudbreak Pharma and its competitors. According to the industry distribution chart, Cloudbreak Pharma ranks #999999 out of 334 companies in the Biotechnology industry.
Is Cloudbreak Pharma's EV-to-FCF too high?
Cloudbreak Pharma's current EV-to-FCF is -1.15. Based on the distribution chart, Cloudbreak Pharma ranks #999999 out of 334 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Cloudbreak Pharma has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Cloudbreak Pharma's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Cloudbreak Pharma ranks #999999 out of 334 companies for EV-to-FCF. This places Cloudbreak Pharma in the lower half of its industry. The industry median EV-to-FCF is 17.55. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 17.55, based on 334 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cloudbreak Pharma and its competitors. For the Biotechnology industry, the median EV-to-FCF is 17.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cloudbreak Pharma's current EV-to-FCF is -1.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cloudbreak Pharma stock overvalued right now?
Cloudbreak Pharma (HKSE:02592) has a current EV-to-FCF of -1.15. The current EV-to-FCF is -1.15. Cloudbreak Pharma's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cloudbreak Pharma (HKSE:02592), the current EV-to-FCF is -1.15 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cloudbreak Pharma Inc is engaged in research and development of ophthalmology biotechnology. The company is a clinical-stage ophthalmology biotechnology company focused on developing treatments for ophthalmic diseases through the proprietary drug discovery and development capabilities, with operations based in the United States and China. The pipeline currently consists of nine drug candidates targeted for treatment of anterior and posterior ophthalmic diseases, including five clinical-stage and four pre-clinical stage candidates. The drugs in the pipeline include CBT-001, CBT-004, CBT-009, and CBT-199.
11GF Score
Get the complete analysis for HKSE:02592
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02592 has been successfully added to your 
